Should You Buy Viking Therapeutics Inc (VKTX) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/26
Based on the data provided, Viking Therapeutics Inc (VKTX) is not a strong buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. While the company has potential in the obesity drug market and strong Phase 2 trial results, the high discontinuation rates, insider selling, and lack of immediate positive trading signals suggest a cautious approach. The stock may be better suited for investors with a higher risk tolerance or those willing to wait for clearer catalysts.
Technical Analysis
The MACD is positive and contracting, indicating a potential weakening of upward momentum. RSI is neutral at 42.186, suggesting no clear overbought or oversold conditions. Moving averages are converging, showing no strong trend. The stock is trading below the pivot level (32.772), with key support at 30.303 and resistance at 35.241.
